BernheimV1, Hal, Checkpoint, bibRecord, 000013

Cardiovascular risk factors in patients before and after antiretrovirals initiation in Sub-Saharan Africa, Temprano trial ANRS 12136 experience

Identifieur interne : 000013 ( Hal/Checkpoint ); précédent : 000012; suivant : 000014

Cardiovascular risk factors in patients before and after antiretrovirals initiation in Sub-Saharan Africa, Temprano trial ANRS 12136 experience

Auteurs : Calixte Haba Hebane Guehi [France]

Source :

RBID : Hal:tel-01498452

Descripteurs français

mix :
- Afrique, Facteurs de risques cardio vasculaires, Obésité, Scores de risques, VIH.
Wicri :
- topic : Afrique, Afrique.

English descriptors

mix :
- Africa, Cardio vascular risks factors, HIV, Obesity, Risk Score.

Abstract

The international initiatives for promoting access to antiretroviral therapy (ART) have reduced HIV- related morbidity and mortality. Meanwhile, there are growing cardiovascular risk factors (CVRF) in developing countries, which are witnessing an epidemiological transition. Our objective was to assess the significance of CVRF before and after initiating antiretroviral therapy in HIV-infected people in Africa. Temprano trial aimed to assess the benefits and risks of early antiretroviral therapy and 6-month isoniazid preventive therapy (IPT) after 30-month follow-up. This study concluded that both interventions are effective to reduce severe morbidity, what led WHO, in 2015, to recommend starting ART immediately if CD4 count drop below 500 cells / mm3. In this study, we assessed the prevalence of CVRF and the significance of obesity and overweight at baseline and after 24 months of ART in particular. We then assess the cardiovascular risk score according to the Framingham equation, with and without lipids, at baseline and at the end of follow-up. There were: (i) a positive correlation between the 2 equations (ii) a sharper increase in cardiovascular risks among women and (iii) no difference in the risk increase according to treatment strategies. Finally, in the long-term follow-up of Temprano trial, we are showing the efficacy of IPT on the reduction of mortality, which brings hope in a context where, despite the on-going epidemiological transition, the causes of deaths are still dominated by Tuberculosis in sub- Saharan Africa.

Url:

https://tel.archives-ouvertes.fr/tel-01498452

Links toward previous steps (curation, corpus...)

to stream Hal, to step Corpus: 000025
to stream Hal, to step Curation: 000025

Links to Exploration step

Hal:tel-01498452

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cardiovascular risk factors in patients before and after antiretrovirals initiation in Sub-Saharan Africa, Temprano trial ANRS 12136 experience</title>
<title xml:lang="fr">Facteurs de risque cardiovasculaire chez les patients avant et après initiation des antirétroviraux en Afrique Sub-Saharienne, expérience de l’Essai Temprano ANRS 12 136</title>
<author><name sortKey="Guehi, Calixte Haba Hebane" sort="Guehi, Calixte Haba Hebane" uniqKey="Guehi C" first="Calixte Haba Hebane" last="Guehi">Calixte Haba Hebane Guehi</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-476572" status="VALID">          <idno type="IdRef">197398162</idno>
          <idno type="RNSR">201622170H</idno>
          <orgName> Bordeaux population health </orgName>
          <orgName type="acronym">BPH</orgName>
          <desc>            <address>              <addrLine>Université de Bordeaux - Case 11 - 146 rue Léo Saignat  33076 Bordeaux cedex</addrLine>
              <country key="FR"></country>
            </address>
            <ref type="url">http://www.bordeaux-population-health.center/</ref>
          </desc>
          <listRelation>            <relation active="#struct-259761" type="direct"></relation>
            <relation active="#struct-302259" type="direct"></relation>
            <relation name="U1219" active="#struct-303623" type="direct"></relation>
          </listRelation>
        <tutelles><tutelle active="#struct-259761" type="direct"><org type="institution" xml:id="struct-259761" status="VALID">          <orgName>Université de Bordeaux</orgName>
          <orgName type="acronym">UB</orgName>
          <desc>            <address>              <addrLine>35, place Pey Berland - 33076 Bordeaux</addrLine>
              <country key="FR"></country>
            </address>
            <ref type="url">http://www.u-bordeaux.fr/</ref>
          </desc>
        </org>
</tutelle>
<tutelle active="#struct-302259" type="direct"><org type="institution" xml:id="struct-302259" status="VALID">          <orgName>Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)</orgName>
          <desc>            <address>              <country key="FR"></country>
            </address>
          </desc>
        </org>
</tutelle>
<tutelle name="U1219" active="#struct-303623" type="direct"><org type="institution" xml:id="struct-303623" status="VALID">          <idno type="IdRef">026388278</idno>
          <orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
          <orgName type="acronym">INSERM</orgName>
          <desc>            <address>              <addrLine>101, rue de Tolbiac, 75013 Paris </addrLine>
              <country key="FR"></country>
            </address>
            <ref type="url">http://www.inserm.fr</ref>
          </desc>
        </org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
<placeName><settlement type="city">Bordeaux</settlement>
<region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
</placeName>
<orgName type="university">Université de Bordeaux</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">HAL</idno>
<idno type="RBID">Hal:tel-01498452</idno>
<idno type="halId">tel-01498452</idno>
<idno type="halUri">https://tel.archives-ouvertes.fr/tel-01498452</idno>
<idno type="url">https://tel.archives-ouvertes.fr/tel-01498452</idno>
<date when="2016-12-22">2016-12-22</date>
<idno type="wicri:Area/Hal/Corpus">000025</idno>
<idno type="wicri:Area/Hal/Curation">000025</idno>
<idno type="wicri:Area/Hal/Checkpoint">000013</idno>
<idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000013</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cardiovascular risk factors in patients before and after antiretrovirals initiation in Sub-Saharan Africa, Temprano trial ANRS 12136 experience</title>
<title xml:lang="fr">Facteurs de risque cardiovasculaire chez les patients avant et après initiation des antirétroviraux en Afrique Sub-Saharienne, expérience de l’Essai Temprano ANRS 12 136</title>
<author><name sortKey="Guehi, Calixte Haba Hebane" sort="Guehi, Calixte Haba Hebane" uniqKey="Guehi C" first="Calixte Haba Hebane" last="Guehi">Calixte Haba Hebane Guehi</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-476572" status="VALID">          <idno type="IdRef">197398162</idno>
          <idno type="RNSR">201622170H</idno>
          <orgName> Bordeaux population health </orgName>
          <orgName type="acronym">BPH</orgName>
          <desc>            <address>              <addrLine>Université de Bordeaux - Case 11 - 146 rue Léo Saignat  33076 Bordeaux cedex</addrLine>
              <country key="FR"></country>
            </address>
            <ref type="url">http://www.bordeaux-population-health.center/</ref>
          </desc>
          <listRelation>            <relation active="#struct-259761" type="direct"></relation>
            <relation active="#struct-302259" type="direct"></relation>
            <relation name="U1219" active="#struct-303623" type="direct"></relation>
          </listRelation>
        <tutelles><tutelle active="#struct-259761" type="direct"><org type="institution" xml:id="struct-259761" status="VALID">          <orgName>Université de Bordeaux</orgName>
          <orgName type="acronym">UB</orgName>
          <desc>            <address>              <addrLine>35, place Pey Berland - 33076 Bordeaux</addrLine>
              <country key="FR"></country>
            </address>
            <ref type="url">http://www.u-bordeaux.fr/</ref>
          </desc>
        </org>
</tutelle>
<tutelle active="#struct-302259" type="direct"><org type="institution" xml:id="struct-302259" status="VALID">          <orgName>Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)</orgName>
          <desc>            <address>              <country key="FR"></country>
            </address>
          </desc>
        </org>
</tutelle>
<tutelle name="U1219" active="#struct-303623" type="direct"><org type="institution" xml:id="struct-303623" status="VALID">          <idno type="IdRef">026388278</idno>
          <orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
          <orgName type="acronym">INSERM</orgName>
          <desc>            <address>              <addrLine>101, rue de Tolbiac, 75013 Paris </addrLine>
              <country key="FR"></country>
            </address>
            <ref type="url">http://www.inserm.fr</ref>
          </desc>
        </org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
<placeName><settlement type="city">Bordeaux</settlement>
<region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
</placeName>
<orgName type="university">Université de Bordeaux</orgName>
</affiliation>
</author>
</analytic>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="mix" xml:lang="en"><term>Africa</term>
<term>Cardio vascular risks factors</term>
<term>HIV</term>
<term>Obesity</term>
<term>Risk Score</term>
</keywords>
<keywords scheme="mix" xml:lang="fr"><term>Afrique</term>
<term>Facteurs de risques cardio vasculaires</term>
<term>Obésité</term>
<term>Scores de risques</term>
<term>VIH</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Afrique</term>
<term>Afrique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The international initiatives for promoting access to antiretroviral therapy (ART) have reduced HIV- related morbidity and mortality. Meanwhile, there are growing cardiovascular risk factors (CVRF) in developing countries, which are witnessing an epidemiological transition. Our objective was to assess the significance of CVRF before and after initiating antiretroviral therapy in HIV-infected people in Africa. Temprano trial aimed to assess the benefits and risks of early antiretroviral therapy and 6-month isoniazid preventive therapy (IPT) after 30-month follow-up. This study concluded that both interventions are effective to reduce severe morbidity, what led WHO, in 2015, to recommend starting ART immediately if CD4 count drop below 500 cells / mm3. In this study, we assessed the prevalence of CVRF and the significance of obesity and overweight at baseline and after 24 months of ART in particular. We then assess the cardiovascular risk score according to the Framingham equation, with and without lipids, at baseline and at the end of follow-up. There were: (i) a positive correlation between the 2 equations (ii) a sharper increase in cardiovascular risks among women and (iii) no difference in the risk increase according to treatment strategies. Finally, in the long-term follow-up of Temprano trial, we are showing the efficacy of IPT on the reduction of mortality, which brings hope in a context where, despite the on-going epidemiological transition, the causes of deaths are still dominated by Tuberculosis in sub- Saharan Africa.</div>
</front>
</TEI>
<hal api="V3">          <titleStmt>            <title xml:lang="en">Cardiovascular risk factors in patients before and after antiretrovirals initiation in Sub-Saharan Africa, Temprano trial ANRS 12136 experience</title>
            <title xml:lang="fr">Facteurs de risque cardiovasculaire chez les patients avant et après initiation des antirétroviraux en Afrique Sub-Saharienne, expérience de l’Essai Temprano ANRS 12 136</title>
            <author role="aut">              <persName>                <forename type="first">Calixte Haba Hebane</forename>
                <surname>Guehi</surname>
              </persName>
              <idno type="halauthorid">1519832</idno>
              <affiliation ref="#struct-476572"></affiliation>
            </author>
            <editor role="depositor">              <persName>                <forename>ABES</forename>
                <surname>STAR</surname>
              </persName>
              <email type="md5">f5aa7f563b02bb6adbba7496989af39a</email>
              <email type="domain">abes.fr</email>
            </editor>
          </titleStmt>
          <editionStmt>            <edition n="v1" type="current">              <date type="whenSubmitted">2017-03-30 09:59:09</date>
              <date type="whenModified">2017-10-18 15:14:02</date>
              <date type="whenReleased">2017-03-30 09:59:10</date>
              <date type="whenProduced">2016-12-22</date>
              <date type="whenEndEmbargoed">2017-03-30</date>
              <ref type="file" target="https://tel.archives-ouvertes.fr/tel-01498452/document">                <date notBefore="2017-03-30"></date>
              </ref>
              <ref type="file" subtype="author" n="1" target="https://tel.archives-ouvertes.fr/tel-01498452/file/GUEHI_CALIXE_HABA_HEBANE_2016.pdf">                <date notBefore="2017-03-30"></date>
              </ref>
            </edition>
            <respStmt>              <resp>contributor</resp>
              <name key="131274">                <persName>                  <forename>ABES</forename>
                  <surname>STAR</surname>
                </persName>
                <email type="md5">f5aa7f563b02bb6adbba7496989af39a</email>
                <email type="domain">abes.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>            <distributor>CCSD</distributor>
            <idno type="halId">tel-01498452</idno>
            <idno type="halUri">https://tel.archives-ouvertes.fr/tel-01498452</idno>
            <idno type="halBibtex">guehi:tel-01498452</idno>
            <idno type="halRefHtml">Médecine humaine et pathologie. Université de Bordeaux, 2016. Français. 〈NNT : 2016BORD0324〉</idno>
            <idno type="halRef">Médecine humaine et pathologie. Université de Bordeaux, 2016. Français. 〈NNT : 2016BORD0324〉</idno>
          </publicationStmt>
          <seriesStmt>            <idno type="stamp" n="STAR">STAR - Dépôt national des thèses électroniques</idno>
            <idno type="stamp" n="U-BORDEAUX">Université de Bordeaux</idno>
            <idno type="stamp" n="INSERM">INSERM - Institut national de la santé et de la recherche médicale</idno>
          </seriesStmt>
          <notesStmt></notesStmt>
          <sourceDesc>            <biblStruct>              <analytic>                <title xml:lang="en">Cardiovascular risk factors in patients before and after antiretrovirals initiation in Sub-Saharan Africa, Temprano trial ANRS 12136 experience</title>
                <title xml:lang="fr">Facteurs de risque cardiovasculaire chez les patients avant et après initiation des antirétroviraux en Afrique Sub-Saharienne, expérience de l’Essai Temprano ANRS 12 136</title>
                <author role="aut">                  <persName>                    <forename type="first">Calixte Haba Hebane</forename>
                    <surname>Guehi</surname>
                  </persName>
                  <idno type="halauthorid">1519832</idno>
                  <affiliation ref="#struct-476572"></affiliation>
                </author>
              </analytic>
              <monogr>                <idno type="nnt">2016BORD0324</idno>
                <imprint>                  <date type="dateDefended">2016-12-22</date>
                </imprint>
                <authority type="institution">Université de Bordeaux</authority>
                <authority type="school">École doctorale Sociétés, politique, santé publique (Bordeaux)</authority>
                <authority type="supervisor">Christine Danel</authority>
                <authority type="jury">Valériane Leroy [Rapporteur]</authority>
                <authority type="jury">Vincent Le Moing [Rapporteur]</authority>
                <authority type="jury">Fabrice Bonnet</authority>
                <authority type="jury">Serge Paul Eholié</authority>
                <authority type="jury">Jean-Baptiste Anzouan</authority>
              </monogr>
            </biblStruct>
          </sourceDesc>
          <profileDesc>            <langUsage>              <language ident="fr">French</language>
            </langUsage>
            <textClass>              <keywords scheme="author">                <term xml:lang="en">Cardio vascular risks factors</term>
                <term xml:lang="en">HIV</term>
                <term xml:lang="en">Africa</term>
                <term xml:lang="en">Obesity</term>
                <term xml:lang="en">Risk Score</term>
                <term xml:lang="fr">Facteurs de risques cardio vasculaires</term>
                <term xml:lang="fr">VIH</term>
                <term xml:lang="fr">Afrique</term>
                <term xml:lang="fr">Obésité</term>
                <term xml:lang="fr">Scores de risques</term>
              </keywords>
              <classCode scheme="halDomain" n="sdv.mhep">Life Sciences [q-bio]/Human health and pathology</classCode>
              <classCode scheme="halTypology" n="THESE">Theses</classCode>
            </textClass>
            <abstract xml:lang="en">The international initiatives for promoting access to antiretroviral therapy (ART) have reduced HIV- related morbidity and mortality. Meanwhile, there are growing cardiovascular risk factors (CVRF) in developing countries, which are witnessing an epidemiological transition. Our objective was to assess the significance of CVRF before and after initiating antiretroviral therapy in HIV-infected people in Africa. Temprano trial aimed to assess the benefits and risks of early antiretroviral therapy and 6-month isoniazid preventive therapy (IPT) after 30-month follow-up. This study concluded that both interventions are effective to reduce severe morbidity, what led WHO, in 2015, to recommend starting ART immediately if CD4 count drop below 500 cells / mm3. In this study, we assessed the prevalence of CVRF and the significance of obesity and overweight at baseline and after 24 months of ART in particular. We then assess the cardiovascular risk score according to the Framingham equation, with and without lipids, at baseline and at the end of follow-up. There were: (i) a positive correlation between the 2 equations (ii) a sharper increase in cardiovascular risks among women and (iii) no difference in the risk increase according to treatment strategies. Finally, in the long-term follow-up of Temprano trial, we are showing the efficacy of IPT on the reduction of mortality, which brings hope in a context where, despite the on-going epidemiological transition, the causes of deaths are still dominated by Tuberculosis in sub- Saharan Africa.</abstract>
            <abstract xml:lang="fr">Les initiatives internationales pour l’accès au traitement antirétroviral (ARV) ont permis une réduction de la morbi-mortalité liée au VIH. Parallèlement, il existe croissance des risques cardio vasculaire (FRCV) dans les pays en développement, témoin d’une transition épidémiologique. Notre objectif était d’évaluer l’importance des FRCV avant et après mise sous antirétroviraux chez des personnes infectées par le VIH en Afrique. L’essai Temprano avait pour objectif d’évaluer les bénéfices et risque du traitement antirétroviral précoce et d’une chimio prophylaxie par 6 mois d’isoniazide (IPT) après 30 mois de suivi. Cette étude a conclu à l’efficacité des 2 interventions sur la réduction de la morbidité sévère, conduisant l’OMS, dès 2015, à recommander les ARV dès que les CD4 sont inférieurs à 500 CD4/mm3. Dans ce travail, nous avons évalué la prévalence des FRCV, et en particulier l’importance de l’obésité et du surpoids, à l’inclusion puis après 24 mois d’ARV. Nous avons ensuite calculé le score de risque cardio vasculaire selon l’équation de Framingham, avec et sans lipides à l’inclusion et à la fin du suivi. Il existait(i) une bonne corrélation des 2 équations (ii) une augmentation plus marquée du risque cardiovasculaire chez les femmes et (iii) une absence de différence de l’augmentation du risque selon les stratégies thérapeutiques. Enfin, dans le suivi long terme de Temprano nous montrons une efficacité de l’IPT sur la réduction de la mortalité, ce qui apporte un espoir dans un contexte où, malgré la transition épidémiologique en cours, les causes de mortalité sont toujours dominées par la Tuberculose en Afrique sub-saharienne.</abstract>
          </profileDesc>
        </hal>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/BernheimV1/Data/Hal/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000013 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Hal/Checkpoint/biblio.hfd -nk 000013 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Psychologie
   |area=    BernheimV1
   |flux=    Hal
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Hal:tel-01498452
   |texte=   Cardiovascular risk factors in patients before and after antiretrovirals initiation in Sub-Saharan Africa, Temprano trial ANRS 12136 experience
}}

This area was generated with Dilib version V0.6.33.
Data generation: Mon Mar 5 17:33:33 2018. Site generation: Thu Apr 29 15:49:51 2021

	Serveur d'exploration Hippolyte Bernheim
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Hippolyte Bernheim

Cardiovascular risk factors in patients before and after antiretrovirals initiation in Sub-Saharan Africa, Temprano trial ANRS 12136 experience

Cardiovascular risk factors in patients before and after antiretrovirals initiation in Sub-Saharan Africa, Temprano trial ANRS 12136 experience

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri